Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN 0401)
Parent Study Contact: Alan Howard, firstname.lastname@example.org
Study Type: Clinical Trial
Prepared on May 31, 2012
Consent: Restricted Consent
Consent Restrictions: For protocol use only
Commercial Use Restrictions: No
Collection Type: Proprietary Study - See bottom of this webpage for request information
The primary objective of this study is to compare progression-free survival (PFS) after autologous Hematopoietic stem cell transplantation (ASCT) for chemotherapy-sensitive diffuse large B-cell lymphoma using Rituxan/BEAM versus Bexxar/BEAM for pre-transplant conditioning.
Interested parties can contact Alan Howard for further details about specimen availability.